Latest news

• Roche undercuts price of Bayer cancer drug after winning FDA approval

  The list price for a month’s supply of Rozlytrek is just over $17, 000, compared to almost $33, 000 for Vitrakvi. ... Writing earlier this year, analysts at Jefferies called Rozlytrek one of Roche’s “lower risk late-stage key oncology assets”.

• CHMP backs Bayer’s tumour-agnostic drug Vitrakvi

  Entrectinib has just been approved in Japan, its first market, as Rozlytrek.

• New products help lift Roche outlook despite biosimilar onslaught

  Finally, the period also saw the approval of two new cancer treatments, Rozlytrek and  Polivy..

• Roche wins FDA priority review for haemophilia A drug

  Emicizumab prophylaxis could be approved early next year

• Pfizer gets FDA OK for expanded use of lung cancer drug Xalkori

  First NSCLC treatment targeting the rare ROS1 mutation to be approved in the US